Measure	Targeted Infectious Agents
General interview and screening	Bloodborne phase of multiple agents
• Previous donor history (ie, no deferral in effect)
• General health, current illness, temperature at time of donation
• Donor confidential unit exclusion optionb
• Remember to notify blood collector of illness (eg, fever, diarrhea after donation, or any other pertinent information recalled)
Specific risk factor history
• High-risk sexual behaviors or injection drug use in donor or donor's partner(s)	HIV, HCV, HBV, HTLV
• Geographic risks (travel and residence)	Malaria, vCJD, leishmaniasis
• History of specific infections	HIV, HBV, HCV, other hepatitis agents, parasites (those causing malaria, Chagas disease, babesiosis, and leishmaniasis)
• Previous parenteral exposure to blood via transfusion or occupational exposure; not lifetime deferral	HIV, HCV, HBV
Laboratory screening	HIV-1 and HIV-2 (HIV antibody and HIV-1 NAA), HCV (antibody), HIV and HCV NAA; HBV (HBsAg and anti-HBc, ALT sometimes is performed but not recommended by the FDA), HTLV-1 and HTLV-2 (antibodies), syphilis (antibodies), WNV (NAA), screens for bacteria

HIV indicates human immunodeficiency virus; HCV, hepatitis C virus; HBV, hepatitis B virus; HTLV, human T-lymphotropic virus; vCJD, variant Creutzfeldt-Jakob disease; NAA, nucleic acid amplification (test); HBsAg, hepatitis B surface antigen; anti-HBc, antibody to hepatitis B core antigen; ALT alanine transaminase; FDA, US Food and Drug Administration; WNV, West Nile Virus.